In-situ truncation method for nonessentials-inducing aptamer in aptamer-protein conjugate and truncated aptamer that is prepared by same method and binds with high affinity to vaspin

The in situ aptamer truncation method using nucleic acid exonucleases effectively removes non-essential sequences from aptamers, enhancing their binding affinity and specificity to target proteins, addressing limitations in existing methods and enabling improved diagnostic and detection applications.

WO2024248491A1PCT designated stage expired Publication Date: 2024-12-05KOREA UNIV RES & BUSINESS FOUND +1
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/007366
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-05-23
Filing Date
2024-05-30
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current aptamer truncation methods fail to effectively remove non-essential sequences that do not bind to target proteins, leading to reduced binding affinity and specificity, and are limited by their inability to consider the actual influence of the target molecule during truncation, especially for DNA aptamers.

Method used

An in situ aptamer truncation method using nucleic acid exonucleases, such as Exo III and T5 exonuclease, to remove non-essential sequences from aptamers while maintaining their binding to target proteins, allowing for the production of truncated aptamers with enhanced binding affinity and specificity.

Benefits of technology

This method improves the binding force and specificity of aptamers to target proteins, reducing steric hindrance and synthesis costs, and enables the development of kits and sensors for disease diagnosis and target substance detection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024007366_05122024_PF_FP_ABST
    Figure KR2024007366_05122024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to: an in-situ truncation method for a nonessentials-inducing aptamer in an aptamer-protein conjugate; and a truncated aptamer that is prepared by the method and binds with high affinity to vaspin. Particularly, the present invention relates to: an in-situ aptamer truncation method comprising the steps of (1) mixing a target protein and an aptamer capable of binding to the target protein to form a conjugate of the aptamer and the target protein and (2) treating the conjugate of the aptamer and the target protein with exonuclease to remove nonessentials of the aptamer that do not bind to the target protein; a truncated aptamer that is prepared by the method and consists of an essential sequence that binds to the target protein; a kit for detecting a target protein, comprising the truncated aptamer; a method for preparing a truncated aptamer that binds to a vaspin protein, by the in-situ aptamer truncation method; and a truncated DNA aptamer that is prepared by the method and consists of an essential sequence that binds to a vaspin protein.
Need to check novelty before this filing date? Find Prior Art

Description

Aptamer-protein complex in situ truncation method for non-essential sequence-guided aptamer and truncated aptamer that binds to vespin with high affinity prepared by the method

[0001] The present technology relates to a non-essential sequence-guided in situ truncation method for aptamer-protein complexes and a truncated aptamer that binds to vespin with high affinity prepared by the method.

[0002] Aptamers are single-stranded DNA or RNA molecular structures with high specificity and affinity for a specific target. They are developed through a known aptamer development method called SELEX (Systematic Evolution of Ligands by Exponential Enrichment). 12-14 Aptamers are screened from random nucleic acid libraries with a high degree of diversity. Unlike antibodies, which are conventional sensing materials, aptamers are nucleic acid structures with excellent thermal stability. Since they are synthesized in vitro, no animals or cells are required, resulting in short screening times, easy modification, and economical production costs. Furthermore, aptamers can recognize a wide range of molecules, including small molecules, proteins, viruses, and cells. Due to the characteristic of aptamers to bind specifically with strong affinity to their targets, recent research is being conducted to apply aptamers to various fields such as new drug development, drug delivery systems, and biosensors.

[0003] Meanwhile, aptamers have limitations in direct clinical and laboratory applications due to issues such as their size and in vivo degradation. To address these issues, post-SELEX studies have been conducted to truncate, chemically modify, or mutagenize aptamers.

[0004] Most aptamer sequences currently developed typically have 60-100 nucleotides, including nonessential sequences that do not participate in target binding and cause reduced binding affinity due to steric hindrance caused by self-stacking and hybridization. Therefore, aptamer truncation, which removes nonessential sequences while leaving only the sequences necessary for target binding, not only enhances the binding affinity and binding specificity of the aptamer, but also increases synthetic yield and reduces synthetic costs due to its short length.

[0005] Aptamer truncation methods currently under development and in progress can be broadly divided into two types: systematic truncation and bioinformatic truncation. Systematic truncation involves removing unnecessary nucleotides one by one from the end of the aptamer sequence. In contrast, bioinformatic truncation selects the aptamer to be cut based on information analyzed from the aptamer sequence. Programs such as Clustal Omega and DNAMAN align aptamer sequences and compare sequence similarities to identify common sequences, which are then considered sequences involved in target binding. In addition, secondary structure prediction programs such as Mfold and RNA structure are used to analyze aptamer secondary structures that may play a key role in target binding, such as hairpins, G-quadruplexes, and T-junctions. That is, the binding site for the target can be predicted through sequence similarity comparison or secondary structure analysis of the aptamer, and other sequences can be eliminated.

[0006] However, these aforementioned methods have limitations in that they analyze the sequence and secondary structure of the aptamer itself, but do not consider the influence of the actual target molecule. Since aptamers undergo structural changes upon binding to their targets, their interactions with the target molecule must be considered when truncation is performed. Therefore, in silico approaches that utilize algorithms that can model aptamer folding and aptamer-target interactions in three dimensions have recently been used. Aptamer tertiary structures can be predicted using online servers such as RNAComposer, 3dRNA, Vfold3D, and SimRNA. The predicted tertiary structure can then be visually represented using molecular docking simulation algorithms such as AutoDock, AutoDock Vina, HADDOCK, and Rosetta to visualize binding to the target. Based on these docking results, the proposed aptamer binding pose and binding site are considered key factors in target binding, and this can be used to determine the site for truncation. However, the determination of aptamers that bind to targets through these three-dimensional structures has only been developed for RNA aptamers, and a prediction algorithm for analyzing the three-dimensional structure of DNA aptamers has not yet been developed.

[0007] Furthermore, even if a base mutation process is added to the algorithm for analyzing the 3D structure of RNA aptamers and applied to the 3D structure of DNA aptamers, the accuracy is low because the results are not direct. Furthermore, during in silico docking, it is difficult to accurately replicate the complex conditions required for aptamer binding to the target, such as metal ion concentration, temperature, and biofluid. Furthermore, the program requires significant hardware capacity, posing a limitation.

[0008] Therefore, there is a need for the development of a simple and direct technique that can maintain the binding state of a DNA aptamer and a protein target, truncate non-essential portions that are not involved in binding, and identify where in the aptamer sequence the portion involved in binding is.

[0009] Accordingly, an object of the present invention is to provide an in situ aptamer truncation method, comprising: (1) a step of mixing a target protein and an aptamer capable of binding to the target protein to form a complex of the aptamer and the target protein; and (2) a step of treating the complex of the aptamer and the target protein with an exonuclease to remove non-essential sequences of the aptamer that do not bind to the target protein.

[0010] Another object of the present invention is to provide a truncated aptamer comprising an essential sequence that binds to a target protein, produced by the in situ aptamer truncation method of the present invention.

[0011] Another object of the present invention is to provide a kit for detecting a target protein, comprising the truncated aptamer of the present invention.

[0012] Another object of the present invention is to provide a method for producing a truncated aptamer that binds to a vaspin protein by an in situ aptamer truncation method, comprising the steps of: (1) forming a complex of an aptamer and a vaspin protein by mixing a vaspin protein and an aptamer capable of binding to the vaspin protein; (2) sequentially treating the complex of the aptamer and the vaspin protein with exonuclease III and T5 exonuclease to remove a non-essential sequence of the aptamer that does not bind to the vaspin protein; and (3) sequencing the sequence of the truncated aptamer consisting of an essential sequence that binds to the vaspin protein.

[0013] Furthermore, another object of the present invention is to provide a truncated DNA aptamer comprising an essential sequence that binds to a Bespin protein, manufactured by the method of the present invention.

[0014] Therefore, the present invention provides an in situ aptamer truncation method, comprising: (1) a step of mixing a target protein and an aptamer capable of binding to the target protein to form a complex of the aptamer and the target protein; and (2) a step of treating the complex of the aptamer and the target protein with an exonuclease to remove a non-essential sequence of the aptamer that does not bind to the target protein.

[0015] In one embodiment of the present invention, the nucleic acid exonuclease can sequentially or simultaneously process two different types of nucleic acid exonuclease.

[0016] In one embodiment of the present invention, the nucleic acid exonuclease can sequentially process exonuclease III and T5 exonuclease.

[0017] In one embodiment of the present invention, the exonuclease III may be added so that the final concentration of the reaction solution is 0.5 to 1.5 U / ㎕, and the T5 exonuclease may be added so that the final concentration of the reaction solution is 0.1 to 0.5 U / ㎕.

[0018] In one embodiment of the present invention, after the step (2), a step of performing a sequencing analysis on the aptamer sequence cleaved by treatment with an external nucleic acid hydrolase and the aptamer sequence binding to the target protein, thereby determining the truncated aptamer sequence binding to the target protein may be further included.

[0019] In addition, the present invention provides a truncated aptamer comprising an essential sequence that binds to a target protein, produced by the in situ aptamer truncation method of the present invention.

[0020] The present invention also provides a kit for detecting a target protein, comprising an aptamer truncated by the method of the present invention.

[0021] In one embodiment of the present invention, the target protein may be a vaspin protein.

[0022] In one embodiment of the present invention, the truncated aptamer may be an aptamer of SEQ ID NO: 3 or SEQ ID NO: 4, which consists of an essential sequence that binds to a vaspin protein.

[0023] In addition, the present invention provides a method for producing a truncated aptamer that binds to a vaspin protein by an in situ aptamer truncation method, comprising the steps of: (1) forming a complex of an aptamer and a vaspin protein by mixing a vaspin protein and an aptamer capable of binding to the vaspin protein; (2) sequentially treating the complex of the aptamer and the vaspin protein with exonuclease III and T5 exonuclease to remove a non-essential sequence of the aptamer that does not bind to the vaspin protein; and (3) sequencing the sequence of the truncated aptamer consisting of an essential sequence that binds to the vaspin protein.

[0024] Furthermore, the present invention provides a truncated DNA aptamer comprising an essential sequence that binds to a Bespin protein, prepared by the method of the present invention.

[0025] In one embodiment of the present invention, the aptamer may be composed of a base sequence of SEQ ID NO: 3 or SEQ ID NO: 4.

[0026] The in situ aptamer truncation method provided by the present invention uses two nucleotide ectohydrolases, Exo III and T5 Exo, to hydrolyze non-essential sequences of the aptamer that do not participate in target binding into single nucleotide units from the 3' and 5' ends while the aptamer maintains binding to the target protein, thereby producing a truncated aptamer composed of essential sequences that actually bind to the target protein. This method of the present invention is a method that has not been reported to date, and has the effect of not requiring any aptamer labeling or engineering, and furthermore, unnecessary sequences of the aptamer that do not participate in binding can be removed, so that not only can the binding affinity and specificity with the target be improved, but also the inhibition and interference of binding can be reduced due to the reduced aptamer size, and it can be usefully utilized in the development of kits or sensors for the diagnosis of various diseases and the detection of target substances.

[0027] Figure 1 is a schematic diagram of an unnecessary sequence-induced aptamer in situ truncation method for an aptamer-protein conjugate according to the present invention.

[0028] Figure 2 shows the degree of degradation over time when treating the V1 aptamer with an external nucleic acid hydrolase III in one embodiment of the present invention, as confirmed by PAGE gel results.

[0029] Figure 3 shows the degree of degradation over time when the V1(3')-44 aptamer is treated with an external nucleic acid hydrolyzing enzyme T5 in one embodiment of the present invention, as confirmed by PAGE gel results.

[0030] Figure 4 shows the degree of degradation over time when treating the V49 aptamer with an external nucleic acid hydrolase III in one embodiment of the present invention, as confirmed by PAGE gel results.

[0031] FIG. 5 shows the degree of degradation over time when the V49(3')-50 aptamer is treated with an external nucleic acid hydrolyzing enzyme T5 in one embodiment of the present invention, as confirmed by PAGE gel results.

[0032] Figure 6 shows the PAGE gel results (a) and the graph (b) quantified using the Image J program after binding the V1 aptamer to the buffer, vaspin, adiponectin, nampt, HSA, Resistin, and RBP4 in order from the left, and then treating it with external nuclease III.

[0033] Figure 7 shows the secondary structure predicted using the Mfold program of the V1(3'-5')-26 aptamer truncated by the method of the present invention.

[0034] Figure 8 shows the secondary structure predicted using the Mfold program of the V49(3'-5')-30 aptamer truncated by the method of the present invention.

[0035] Figure 9 shows the results of comparing the binding specificity of the existing V1 aptamer and the V1(3'-5')-26 aptamer truncated by enzyme treatment.

[0036] Figure 10 shows the results of comparing the binding specificity of the existing V49 aptamer and the V49(3'-5')-30 aptamer truncated by enzyme treatment.

[0037] Figure 11 shows an analysis of the binding affinity of the V1(3'-5')-26 aptamer according to the present invention to vaspin.

[0038] Figure 12 shows an analysis of the binding affinity of the V49(3'-5')-30 aptamer according to the present invention to vaspin.

[0039] FIG. 13 shows the results of analyzing the binding form and degree of binding to vaspin using each aptamer pair using ELASA (Enzyme-linked aptamer-based sandwich assay) and CLSM in one embodiment of the present invention, where A is a schematic diagram of the ELASA analysis process, B is the ELASA analysis result for the aptamer pair of the first or second aptamer based on the optical density (OD) ratio of 200 nM vaspin to the buffer (OD target / OD buffer), and C is a microscope image of the binding form to the target protein using the truncated V49(3'-5')-30 and V1(3'-5')-26 aptamer pair (scale bar: 20 μm).

[0040] The present invention relates to an in situ aptamer truncation method, which comprises a step of treating an aptamer with an exonuclease while the aptamer is bound to a target protein to remove a non-essential sequence of the aptamer that does not bind to the target protein.

[0041] Specifically, the present invention is characterized by providing an in situ aptamer truncation method, which comprises (1) a step of mixing a target protein and an aptamer capable of binding to the target protein to form a complex of the aptamer and the target protein; and (2) a step of treating the complex of the aptamer and the target protein with an exonuclease to remove a non-essential sequence of the aptamer that does not bind to the target protein.

[0042] As previously mentioned in the prior art, a typical aptamer sequence is composed of 60 to 100 nucleotides, which include non-essential sequences that do not bind to the target. This unnecessary sequence causes a problem in that it reduces binding affinity to the target due to steric hindrance caused by self-stacking and hybridization.

[0043] However, as a technology that can practically and effectively solve these problems has not been developed, the inventors of the present invention have conducted research to improve these problems and have established a new method for removing, or truncating, non-essential sequences of aptamers that do not bind to the target.

[0044] The method according to the present invention is performed through a process of hydrolyzing a non-essential aptamer sequence that does not bind to the target protein by treating two different types of nucleic acid external hydrolases while maintaining the complex of the aptamer and the target protein.

[0045] In the present invention, 'aptamer' refers to a small single-stranded oligonucleotide nucleic acid that can specifically recognize a target substance with high affinity.

[0046] In particular, the aptamer to be truncated in the present invention may preferably be a DNA aptamer. The term "DNA aptamer" refers to a DNA nucleic acid molecule capable of binding to a specific molecule with high affinity and specificity.

[0047] Additionally, the DNA aptamer may include a ligand capable of specifically binding to the DNA aptamer. The ligand may be a conjugate labeled with a detector such as a chromogenic enzyme, a fluorescent substance, a radioisotope, or a colloid, and a ligand treated with streptavidin or avidin.

[0048] In addition, in the present invention, 'exonuclease' refers to an enzyme that can decompose nucleotides from the end of nucleic acid by hydrolyzing phosphodiester bonds. Two types of exonuclease were used in the present invention, exonuclease III and T5 exonuclease. Exonuclease III is an enzyme that sequentially decomposes DNA from the 3' end, and T5 exonuclease is an exonuclease that sequentially decomposes DNA from the 5' end.

[0049] In addition, in the present invention, the term 'nonessential sequence' refers to a part of the aptamer sequence that does not participate in binding when the aptamer binds to a target protein, and the term 'essential sequence' refers to a part of the aptamer sequence that actually participates in binding to a target protein.

[0050] Specifically, the in situ aptamer truncation method according to the present invention is described step by step with reference to FIG. 1 as follows.

[0051] First, (1) a target protein and an aptamer capable of binding to the target protein are mixed to form a complex of the aptamer and the target protein.

[0052] That is, it is a step of mixing the aptamer and the target protein in a buffer solution and inducing binding of the aptamer and the target protein at room temperature.

[0053] In one embodiment of the present invention, vaspin protein was used as a target protein, and the V1 or V49 aptamer of sequence number 1 or sequence number 2, which is a known aptamer that binds to the vaspin protein, was used. The vaspin protein and the aptamer were added to a buffer solution and mixed, and then a binding reaction was induced at room temperature (25°C).

[0054] Afterwards, (2) a process is performed in which the non-essential sequence of the aptamer that does not bind to the target protein is removed by treating the complex of the aptamer and the target protein with an exonuclease.

[0055] The above step (2) is a step of treating and reacting with an external nucleic acid hydrolase while maintaining the binding between the aptamer and the target protein, thereby hydrolyzing non-essential bases of the aptamer that do not bind to the target protein.

[0056] At this time, the nucleic acid exonuclease can react by sequentially or simultaneously treating two different types of nucleic acid exonuclease, and preferably, it can react by sequentially treating two different types of nucleic acid exonuclease.

[0057] As an example of the above sequential processing, a process may be performed in which exonuclease III is first processed as a nucleic acid exonuclease, and then T5 exonuclease is processed, or the order of the enzymes may be changed.

[0058] In one embodiment of the present invention, for a complex of a vaspin protein and an aptamer, exonuclease III was added to the reaction solution at a final concentration of 0.5 to 1.5 U / ㎕ and the reaction was conducted at room temperature, so that the sequence of the aptamer that did not participate in binding to the vaspin protein was hydrolyzed from the 3' end. Then, for the complex of the aptamer and the target protein, from which the sequence that did not participate in binding to the vaspin protein was removed by the exonuclease III treatment, T5 exonuclease was added to the reaction solution at a final concentration of 0.1 to 0.5 U / ㎕ and the reaction was conducted at room temperature, so that this time the sequence of the aptamer that did not participate in binding to the vaspin protein was hydrolyzed from the 5' end.

[0059] Through this process, non-essential sequences of the aptamer that do not participate in binding to the target protein were removed from the 3' end and 5' end of the aptamer, thereby finally obtaining an aptamer composed of essential sequences that actually participate in binding to the target protein.

[0060] In addition, the essential aptamer sequence participating in binding to the target protein at this time can be confirmed and determined by performing a sequencing analysis on the aptamer sequence cleaved by treatment with an external nucleic acid hydrolase and the aptamer sequence binding to the target protein after step (2).

[0061] The above sequencing analysis can confirm the length and sequence information of the cut aptamer by taking a portion of the reaction solution at regular intervals after the nucleic acid external hydrolase treatment and performing polyacrylamide gel electrophoresis and NGS (next generation sequencing) analysis.

[0062] When the complex of the aptamer and the target protein is treated with an external nuclease, the aptamer sequence bound to the target protein cannot be acted on by the external nuclease due to structural interference by the target protein, and thus the hydrolysis of the aptamer sequence by the enzyme is stopped, whereas the aptamer that does not participate in binding to the target protein is completely hydrolyzed from the 3' end or 5' end by the external nuclease. Therefore, when the in situ aptamer truncation method according to the present invention is performed, a truncated aptamer composed of an essential sequence that substantially participates in binding to the target protein can be obtained.

[0063] Therefore, the present invention can provide a truncated aptamer comprising an essential sequence that binds to a target protein generated by the in situ aptamer truncation method of the present invention.

[0064] In one embodiment of the present invention, a truncated aptamer having SEQ ID NO: 3 and SEQ ID NO: 4 that substantially participates in binding to the Bespin protein was prepared using the in situ aptamer truncation method of the present invention, with Bespin as the target protein.

[0065] The truncated aptamer of the above sequence number 3 is a 76 mer vespin-binding V1 aptamer (SEQ ID NO: 1) that was cleaved into a 44 mer V1(3')-44 aptamer by hydrolyzing the non-essential sequence through treatment with an external nuclease III, and then finally produced as a 26 mer V1(3'-5')-26 truncated aptamer by hydrolyzing the non-essential sequence through treatment with an external nuclease T5.

[0066] In addition, the truncated aptamer of the above sequence number 4 was produced by cleaving the 66-mer vespin-binding V49 aptamer (SEQ ID NO: 2) into a 50-mer V49(3')-50 aptamer through hydrolysis of the non-essential sequence by treatment with an external nuclease III, and then finally producing a 30-mer V49(3'-5')-30 truncated aptamer through hydrolysis of the non-essential sequence by treatment with an external nuclease III.

[0067] In another embodiment of the present invention, binding specificity and binding affinity were analyzed for a truncated aptamer composed of essential sequences that participate in binding to a Bespin target protein.

[0068] As a result, it was found that the aptamer truncated by the method of the present invention had significantly higher binding affinity for the target protein compared to the aptamer that did not undergo the truncation process, and the truncated aptamer was found to have binding specificity only for the target protein and did not bind to proteins other than the target protein.

[0069] Through this, the inventors of the present invention were able to find out that when using a truncated aptamer by the method of the present invention, the target protein can be efficiently detected with higher binding specificity and binding affinity.

[0070] Accordingly, the present invention can provide a kit for detecting a target protein, which includes an aptamer truncated by the method of the present invention.

[0071] The truncated aptamer according to the present invention can be used to directly detect a target protein or to detect a target protein in a biological sample, and can further be used to diagnose diseases.

[0072] The above biological sample may include any sample for which a target protein is to be detected. For example, the sample may be a mammalian sample, and more specifically, a human sample. Furthermore, the sample may be at least one selected from the group consisting of blood, body fluid, saliva, tears, urine, synovial fluid, mucus, cells, and tissue.

[0073] Additionally, the sample may be pretreated using a method such as anion exchange chromatography, affinity chromatography, size exclusion chromatography, liquid chromatography, continuous extraction, centrifugation or gel electrophoresis before being used in the method according to the present invention.

[0074] The kit for detecting a target protein of the present invention is based on a method for detecting a complex of a truncated DNA aptamer that specifically binds to a target protein and a target protein.

[0075] Additionally, the kit of the present invention may further include instructions or labels for using the kit to detect a target protein in a sample.

[0076] The kit according to the present invention can be bound to a solid substrate to facilitate subsequent steps, such as washing the DNA aptamer included therein or separating the complex. The solid substrate may be a synthetic resin, nitrocellulose, a glass substrate, a metal substrate, glass fiber, microspheres, or microbeads. Furthermore, the synthetic resin may be polyester, polyvinyl chloride, polystyrene, polypropylene, PVDF, or nylon.

[0077] In addition, the kit can be manufactured by a conventional manufacturing method known to those skilled in the art, and may further include a buffer, a stabilizer, an inactive protein, etc. The kit can use a high throughput screening (HTS) system using a fluorescence method performed by detecting the fluorescence of a fluorescent substance attached as a detector to search for the amount of a reagent, a radiological method performed by detecting the radiation of a radioisotope attached as a detector, a surface plasmon resonance (SPR) method for measuring the plasmon resonance change of the surface of the detector in real time without labeling, or a surface plasmon resonance imaging (SPRI) method for confirming by imaging the SPR system.

[0078] In addition, the truncated DNA aptamer of the present invention can be manufactured in the form of a biosensor and sensor chip including an immobilized substrate and used to detect a target protein.

[0079] The above “biosensor and sensor chip” refers to a sensor and chip in which a specific material is densely attached to a specific area of ​​a substrate. In the present invention, the “substrate” of the biosensor and sensor chip refers to a support having suitable rigidity or semi-rigidity, and includes, but is not limited to, glass, a membrane, a slide, a filter, a chip, a wafer, a fiber, a magnetic bead or a non-magnetic bead, a gel, a tubing, a plate, a polymer, microparticles, and a capillary.

[0080] The DNA aptamer of the present invention can be arranged and immobilized on the substrate. Such immobilization can be achieved by chemical bonding or covalent bonding, such as UV irradiation. For example, the DNA oligonucleotide can be bound to a glass surface modified to include an epoxy compound or an aldehyde group, and can also be bound to a polylysine-coated surface by UV irradiation. Furthermore, the DNA oligonucleotide can be bound to the substrate via a linker (e.g., an ethylene glycol oligomer and a diamine).

[0081] In one embodiment of the present invention, a sandwich-type detection sensor was manufactured by forming a sandwich-type bond of aptamer-target (target protein)-aptamer on a substrate, and the possibility of detecting the target protein was confirmed through experiments.

[0082] Sandwich-type sensors require two different receptors (or aptamers) that bind to different sites on a single target substance. Sandwich-type biosensors are widely used due to their diverse uses, including labeling with fluorescent dyes, quantum dots, radioactive labels, gold nanoparticles, enzymes, enzyme substrates, and electrochemical functional groups, which can enhance their sensitivity. Therefore, sandwich-type biosensors using aptamers require two or more types of dual aptamers that bind to different sites on a single target substance.

[0083] In this respect, in one embodiment of the present invention, a truncated aptamer capable of binding to a Bespin target protein with high binding affinity was manufactured, and it was found that two different types of manufactured aptamers can be used to manufacture a sandwich-type Bespin protein detection sensor.

[0084] Furthermore, the present invention can provide a method for producing a truncated aptamer that binds to a vaspin protein by an in situ aptamer truncation method, comprising: (1) a step of forming a complex of an aptamer and a vaspin protein by mixing a vaspin protein and an aptamer capable of binding to the vaspin protein; (2) a step of sequentially treating the complex of the aptamer and the vaspin protein with exonuclease III and T5 exonuclease to remove a non-essential sequence of the aptamer that does not bind to the vaspin protein; and (3) a step of sequencing a sequence of a truncated aptamer composed of an essential sequence that binds to the vaspin protein.

[0085] In the present invention, the above 'vaspin' is known as an adipocytokine, and its full name is 'visceral adipose tissue-derived serpin (vaspin)', which may be a protein consisting of an amino acid sequence of sequence number 5.

[0086] In addition, the present invention can provide a truncated DNA aptamer comprising an essential sequence that binds to a Bespin protein manufactured by the above method, and specifically, the truncated DNA aptamer comprising an essential sequence that binds to the Bespin protein can be composed of a base sequence of SEQ ID NO: 3 or SEQ ID NO: 4.

[0087] Hereinafter, the present invention will be described in more detail through examples according to the present invention, but the scope of the present invention is not limited by the examples presented below.

[0088]

[0089] <Prepare the ingredients>

[0090] All oligonucleotides were synthesized and purified using polyacrylamide gel electrophoresis (PAGE) by Bioneer Co. (Daejeon, Korea). Oligonucleotides were dissolved in PCR-grade water, and their concentrations were measured using a Nanodrop 2000 spectrophotometer (Thermo Scientific). All adipokines, including vaspin, adiponectin, visfatin (nampt), retinol-binding protein 4 (RBP4), and resistin, were purchased from Adipogen. Human serum albumin (HSA) and other chemicals were purchased from Sigma-Aldrich unless otherwise specified. Exonuclease III (Exo III) and T5 exonuclease (T5 Exo) (both from Escherichia coli) were purchased from New England Biolabs.

[0091]

[0092] <Example 1>

[0093] Performing in situ aptamer truncation based on non-essential sequence-guided aptamer protein conjugates and identifying truncated aptamers.

[0094] The present inventors performed non-essential sequence-guided in situ truncation using the V1 and V49 aptamers, which are aptamers that specifically bind to the Vaspin protein. The V1 and V49 aptamers are 76-mer and 66-mer, respectively, and their sequences are as follows.

[0095] V1 aptamer sequence (SEQ ID NO: 1):

[0096] 5'-CGTACGGAATTCGCTAGCTGATGGTGTGGCGGGGGCGGCCTGGGGCGGGCCGCCGATGGGATCCGAGCTCCACGTG-3'

[0097] V49 aptamer sequence (SEQ ID NO: 2):

[0098] 5'-CGTACGGAATTCGCTAGCGGTGGCTCTAGGGCCTATCGTTGCGCCGACGGATCCGAGCTCCACGTG-3'

[0099]

[0100] <1-1> Treatment with nucleotide exosomes III

[0101] The above aptamer was mixed with the Vespin protein (Vaspin, Vaspin protein from Edipogen, Prod. No. AG-40A-0064Y) in a buffer solution (20 mM Tris-HCl, pH 7.6, 100 mM NaCl, 2 mM MgCl2, 5 mM KCl, 1 mM CaCl2) and reacted at room temperature for 1 hour. In addition, a group to which the same amount of buffer solution was added instead of the Vespin protein was used as a control group. Thereafter, in order to remove the portion of the aptamer that was not bound to the target protein, exonuclease III (Exo III) was added to the above mixture so that the final concentration was 1 U / μL, and the reaction was performed at room temperature. At this time, the temperature was precisely set to 25℃ using a thermostat. At regular intervals, 5 μL of the mixture was taken and 10 μL of formamide loading buffer solution (75% formamide, 10% glycerol, 0.125% SDS, 25 mM EDTA, and 0.05% bromophenol blue) was added to stop the enzyme reaction.

[0102] Afterwards, 15 μL of the above mixture was heat-treated at 95 °C for 10 minutes, and the sample was loaded onto a 20% denaturing polyacrylamide gel (polyacrylamide gel electrophoresis, PAGE). At this time, the PAGE gel was made by adding 30 μL of 20% APS and 10 μL of TEMED to 12 mL of 20% PAGE solution (DNA-PAGE 20% (19:1) ULTRA PURE, Prod. No. BD011, Biosolution), and making a gel for 1 hour in a glass gel cassette. In addition, 15 μL of a homemade ssDNA size marker was also loaded during sample loading. The homemade ssDNA size markers consisted of 20-, 23-, 26-, 29-, 32-, 35-, 40-, 44-, 50-, 55-, and 60-nt strands, each at 1 μM, which were prepared by removing nucleotides from the 3' end of the V1 aptamer (see Table 1). The gel loaded with the samples was electrophoresed in 1X TBE buffer at a speed of 15 V / cm for 2 h 30 min. Afterwards, the gel was stained with gel staining solution (1X GelRed) for 5 min and confirmed with a GelDoc instrument.

[0103]

[0104] In the electrophoresis analysis, it was found that nothing remained in the control group, and in the experimental group to which the Bespin protein of the present invention was added, the length of the remaining sequence was confirmed by comparing it with the size marker under the time conditions in which the band remained.

[0105] In addition, to prepare a sample for NGS (Next Generation Sequencing), 40 μL of 25 mM EDTA solution was added to 20 μL of the above mixture to stop the enzyme reaction, and a sample was prepared using a purification and concentration kit (oligo clean-up and concentration kit, Prod. No. 34100, Norgen Biotek), and then NGS was performed to obtain base sequence information.

[0106]

[0107] As a result of the analysis, the aptamer V1 for the Vaspin protein was found to be cleaved by treatment with an external nuclease III and had a size of 44-mer, which the inventors named 'V1(3')-44', and another aptamer, V49, was found to have a size of 50-mer, which they named 'V49(3')-50' (see Figs. 2 and 4).

[0108]

[0109] <1-2> Treatment with nucleic acid external hydrolase T5

[0110] After the above treatment with the exo-nucleic acid hydrolase III (Exo III) was completed, the first-obtained V1(3')-44 and V49(3')-50 truncated aptamers were treated under the same conditions so that the final concentration of the exo-nucleic acid hydrolase T5 (T5 Exo) was 0.1 U / μL and reacted. The experiment was performed under the same conditions as <1-1> except that the enzyme used was the exo-nucleic acid hydrolase T5. In addition, Table 2 below shows the top 5 sequences with the highest counts after NGS for the truncated aptamer samples treated with the exo-nucleic acid hydrolase.

[0111]

[0112] Analysis results showed that in the control group, nothing remained over time after enzyme treatment. In the experimental group (protein target treatment), the length of the aptamer sequence was observed to decrease due to enzyme treatment, eventually reaching a specific length. Furthermore, the length was analyzed by comparing it to a self-created size marker.

[0113] As a result, in the case of the V1 aptamer, the 44-mer long V1(3')-44 aptamer was counted the most by Exo III treatment, and the 26-mer long aptamer was counted the most by T5 Exo treatment, so the inventors named it 'V1(3'-5')-26 truncated aptamer'. In the case of the V49 aptamer, the 50-mer long V49(3')-50 aptamer was counted the most by Exo III treatment, and the 30-mer long aptamer was counted the most by T5 Exo treatment, so the inventors named it 'V49(3'-5')-30 truncated aptamer' (see FIGS. 3 and 5).

[0114]

[0115] After performing non-essential sequence-induced aptamer truncation on the V1 and V49 aptamers, the two truncated aptamer sequences were finally obtained. Aptamer name Sequence (5'->3') Sequence number V1 (3'-5') - 26TGATGGTGTGGCGGGGGCGGCCTGGG3 V49 (3'-5') - 30GGCTCTAGGGCCTATCGTTGCGCCGACGGA4

[0116] In addition, it was confirmed that the sequence information with the highest count among the sequence information obtained from the NGS results in Table 2 matches the sequence information that can be extracted in length from the PAGE analysis results in Figures 2 to 5.

[0117]

[0118] <Example 2>

[0119] Confirmation of target binding specificity of truncated aptamer according to the present invention

[0120] First, the inventors reacted the V1 aptamer with vaspin as well as other adipokine proteins (adiponectin, visfatin, RBP4, and resistin) and HSA, and then performed a nonessential sequence-guided aptamer truncation reaction, and confirmed the results by PAGE electrophoresis.

[0121]

[0122] As a result, as shown in Fig. 6, the V1 aptamer was found to show a band only in the sample bound to the vaspin protein, and no band was observed in the experimental groups reacting with other adipokines and HSA. In other words, through these results, the inventors were able to determine that the cessation of degradation by an external nuclease was not due to the protein molecule itself, but rather due to the binding of the target protein to the aptamer.

[0123]

[0124] In addition, the inventors of the present invention analyzed the secondary structures of the V1(3'-5')-26 truncated aptamer and the V49(3'-5')-30 truncated aptamer for vespin truncated by treatment with Exo III and T5 Exo in the above <Example 1> using the Mfold program.

[0125] As a result, the secondary structure of the V1(3'-5')-26 truncated aptamer is shown in Fig. 7, and the secondary structure of the V49(3'-5')-30 truncated aptamer is shown in Fig. 8.

[0126]

[0127] Furthermore, the inventors of the present invention conducted an experiment to confirm whether the V1(3'-5')-26 truncated aptamer and the V49(3'-5')-30 truncated aptamer obtained by the method of the present invention specifically bind only to vaspin and not to other blood proteins. To this end, the aptamers were immobilized on a gold chip and analyzed using a surface plasmon resonance (SPR) device. Specifically, carboxyl groups (-COOH) were created on the gold surface of the chip with 50 mM 3,3'-dithiodipropionic acid, and then a self-assembly monolayer was formed using EDC / NHS. Streptavidin was immobilized thereon, and each aptamer to which biotin was attached was immobilized. Here, 100 nM vaspin and control proteins and HSA were prepared in a buffer solution (20 mM Tris-HCl, pH 7.6, 100 mM NaCl, 2 mM MgCl2, 5 mM KCl, 1 mM CaCl2) and allowed to flow, and then unbound proteins were washed away with the same buffer solution. Finally, the SPR results were analyzed. At this time, since vaspin is one of the adipokines, the group treated with other adipokine proteins, such as Adiponectin, Nampt, RBP4, Resistin, and HSA, was used as the control group.

[0128]

[0129] As a result, as shown in FIGS. 9 and 10, the V1(3'-5')-26 truncated aptamer and the V49(3'-5')-30 truncated aptamer obtained by the method of the present invention were found to bind specifically only to vaspin, and to have little or no binding affinity to other proteins belonging to the edipokine group used as controls.

[0130]

[0131] Through these results, the inventors of the present invention were able to find that the V1(3'-5')-26 truncated aptamer and the V49(3'-5')-30 truncated aptamer according to the present invention, in which the non-essential sequence for aptamer and protein binding is truncated, have excellent binding specificity that can bind only to the target protein, vaspin.

[0132]

[0133] <Example 3>

[0134] Confirmation of high affinity of aptamer truncated by the method of the present invention for target protein

[0135] Furthermore, the inventors of the present invention performed a binding affinity analysis for the two aptamers, the V1(3'-5')-26 truncated aptamer and the V49(3'-5')-30 truncated aptamer, obtained by truncating the method of the present invention, to the vaspin target protein. To this end, the aptamers were immobilized on a gold chip in the same manner as in Example 2, and then vaspin at different concentrations ranging from 0 nM to 400 nM (or 800 nM) was flowed in a buffer solution (20 mM Tris-HCl, pH 7.6, 100 mM NaCl, 2 mM MgCl2, 5 mM KCl, 1 mM CaCl2) to react, and then the unbound protein was washed away with the same buffer solution. To obtain the dissociation constant, the degree of each reaction was plotted using SigmaPlot with nonlinear regression and single-site saturated ligand binding, and analyzed using the formula Y=Bmax*X^h / (Kd^h + X^h) (y is the degree of saturation, Bmax is the maximum binding site, Kd is the dissociation constant, X is the unbound vaspin, h is the hill slope constant).

[0136]

[0137] As a result, the Kd values ​​of the V1(3'-5')-26 truncated aptamer and the V49(3'-5')-30 truncated aptamer were found to be 55 nM and 170 nM, respectively, indicating that they strongly bind to vaspin. Meanwhile, it was found that the binding affinity for vaspin was significantly improved compared to the V1 aptamer (Kd, 150 nM) and the V49 aptamer (Kd, 240 nM), which are aptamers that were not truncated by the method of the present invention (see Figs. 11 and 12).

[0138]

[0139] <Example 4>

[0140] Confirmation of simultaneous binding of truncated aptamers to target proteins at different binding sites by the method of the present invention

[0141] Next, the inventors of the present invention performed an ELASA experiment to confirm the binding site for the target protein, Bespin, on the V1(3'-5')-26 truncated aptamer and the V49(3'-5')-30 truncated aptamer prepared by treating the two types of nucleic acid exosomes in the above example. To this end, an aptamer pair without truncation and a truncated aptamer pair were compared through ELASA analysis. That is, the primary aptamer labeled with biotin was immobilized on a streptavidin-coated plate to capture the target, and the captured target was bound by the secondary aptamer conjugated with HRP to form an aptamer-target-aptamer sandwich bond along with a signal generated by the TMB reaction. The principle of the reaction is shown in Figure 13A.

[0142]

[0143] As a result of the analysis, the binding signal with the Bespin protein was analyzed for the groups using the aptamer pairs that did not undergo truncation and the aptamer pairs that did undergo truncation, and as shown in Fig. 13B, among the groups using the eight aptamer pairs, the group using the V49(3'-5')-30 truncated aptamer as the primary capture aptamer and the V1(3'-5')-26 truncated aptamer as the secondary aptamer showed the highest signal, followed by the group using the V1(3'-5')-26 truncated aptamer as the primary aptamer and the V49(3'-5')-30 truncated aptamer as the secondary aptamer.

[0144] Through the results of FIG. 13B, the inventors of the present invention were able to find out that using an aptamer subjected to truncation by the method of the present invention can detect a target protein more effectively than using an aptamer that has not been truncated, and that a combination of using a V49(3'-5')-30 truncated aptamer and a V1(3'-5')-26 truncated aptamer as the first and second aptamers, respectively, can most effectively detect a target protein in a sandwich configuration.

[0145] In addition, the sandwich-type binding form of the aptamer pair of the present invention and the target protein was analyzed by confocal laser scanning microscopy (CLSM). That is, the biotin-labeled V49(3'-5')-30 and V1(3'-5')-26 truncated aptamers were conjugated to streptavidin-coated magnetic beads (MB) and quantum dots (QD), respectively, and when incubated with the Bespin target protein, a strong fluorescent signal was observed. On the other hand, no signal was detected in the buffer (Fig. 13C).

[0146]

[0147] Through this, the inventors of the present invention were able to confirm that the truncated aptamer pair by the method of the present invention can bind to the target protein in a sandwich form, and that the binding sites with the target protein are different, and that such an aptamer pair can be usefully used in sandwich-type electrochemical aptamer sensors for disease diagnosis.

[0148]

[0149] Through the above results, the inventors of the present invention were able to find that when the aptamer truncation method of the present invention, which cleaves non-essential aptamer portions that are not involved in binding while maintaining the binding state of the DNA aptamer and the target protein using two types of nucleic acid external hydrolases, is applied, unnecessary sequences of the aptamer that are not involved in binding can be removed, thereby reducing steric hindrance, improving the binding affinity and binding strength of the aptamer to the target protein, and reducing the size of the aptamer, thereby enabling expansion of the application field.

[0150]

[0151] The present invention has been described above, focusing on preferred embodiments thereof. Those skilled in the art will appreciate that the present invention can be implemented in modified forms without departing from its essential characteristics. Therefore, the disclosed embodiments should be considered illustrative rather than limiting. The scope of the present invention is set forth in the claims, not the foregoing description, and all differences within the scope equivalent thereto should be construed as being encompassed by the present invention.

Claims

1. (1) A step of forming a complex of the aptamer and the target protein by mixing a target protein and an aptamer capable of binding to the target protein; and (2) A step of treating the complex of the aptamer and the target protein with an exonuclease to remove non-essential sequences of the aptamer that do not bind to the target protein, In situ aptamer truncation method.

2. In paragraph 1, The above nucleic acid exonuclease is a method characterized in that two different types of nucleic acid exonuclease are processed sequentially or simultaneously.

3. In paragraph 2, The above nucleic acid exonuclease is a method characterized in that it sequentially processes nucleic acid exonuclease III and T5 exonuclease.

4. In paragraph 3, A method characterized in that the above nucleic acid external hydrolase III is added so that the final concentration of the reaction solution is 0.5 to 1.5 U / ㎕, and the above T5 nucleic acid external hydrolase T5 exonuclease is added so that the final concentration of the reaction solution is 0.1 to 0.5 U / ㎕.

5. In paragraph 1, A method characterized in that, after the above step (2), a step is further included in which a sequence analysis is performed on the aptamer sequence cleaved by treatment with an external nucleic acid hydrolase and the aptamer sequence binding to the target protein, thereby determining the truncated aptamer sequence binding to the target protein.

6. A truncated aptamer comprising an essential sequence that binds to a target protein produced by the in situ aptamer truncation method of any one of claims 1 to 5.

7. A kit for detecting a target protein, comprising the truncated aptamer of clause 6.

8. In paragraph 6, A truncated aptamer, characterized in that the target protein is a vaspin protein.

9. In paragraph 8, A truncated aptamer, characterized in that the truncated aptamer is an aptamer having SEQ ID NO: 3 or SEQ ID NO: 4, which is composed of an essential sequence that binds to a vaspin protein. 10.(1) A step of forming a complex of the aptamer and the vaspin protein by mixing the vaspin protein and an aptamer capable of binding to the vaspin protein; (2) a step of sequentially treating the complex of the aptamer and the Bespin protein with exonuclease III and T5 exonuclease to remove non-essential sequences of the aptamer that do not bind to the Bespin protein; and (3) a step of sequencing the sequence of a truncated aptamer comprising an essential sequence that binds to a Bespin protein; A method for preparing a truncated aptamer that binds to a vespin protein by an in situ aptamer truncation method.

11. A truncated DNA aptamer comprising an essential sequence that binds to a Bespin protein, manufactured by the method of claim 10.

12. In paragraph 11, The above aptamer is a truncated DNA aptamer comprising an essential sequence that binds to a vespin protein, characterized in that the aptamer comprises a base sequence of SEQ ID NO: 3 or SEQ ID NO: 4.

Citation Information

Patent Citations

  • Method for rapidly screening aptamer based on exonuclease degradation rate

    CN115927535A

  • Aptamer having specific binding ability for vaspin and Biosensor Using therof

    KR101649729B1

  • Systems and methods for nuclease-assisted selection and acquisition of single stranded DNA oligomer / polymer aptamers / ligands

    US20100152056A1

  • lariat aptamer: aptamer candidate exclusion by nuclease digestion

    US20110251088A1

  • Aptamer digestion method

    US20190112634A1